Logo

BeiGene and Asieris Enter into Clinical Collaboration for APL-1202 + Tislelizumab to Treat Muscle Invasive Bladder Cancer

Share this

BeiGene and Asieris Enter into Clinical Collaboration for APL-1202 + Tislelizumab to Treat Muscle Invasive Bladder Cancer

Shots:

  • BeiGene and Asieris collaborate to evaluate the safety and efficacy of APL-1202 + tislelizumab as neoadjuvant therapy in patients with MIBC. APL-1202 has been approved to treat patients with locally advanced or metastatic UC and high expression of PD-L1 who failed to receive platinum-based CT
  • Asieris plans to submit INDs in China and the US for P- I/II clinical study and determine the RP2D (recommended P-II dose)
  • APL-1202 is an orally reversible MetAP2 Inhibitor with anti-angiogenic- anti-tumor activities- currently in P- III clinical trials in China as monthx for the 1L treatment of non-muscle invasive for the 2L treatment of NMIBC

  Ref: PRNewswire | Image: BeiGene

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions